沃华医药(002107.SZ)：2025年净利润同比增长162.93% 拟10股派1.46元

Core Viewpoint -沃华医药 reported a revenue of 816.95 million yuan for the year 2025, marking a year-on-year growth of 6.96% and a net profit attributable to shareholders of 95.72 million yuan, which represents a significant increase of 162.93% [1] Revenue Breakdown - The cardiovascular system drug revenue reached 568.81 million yuan, showing a year-on-year increase of 12.31% [1] - The musculoskeletal system drug revenue was 182.50 million yuan, experiencing a slight decline of 2.03% year-on-year [1] - The antiviral respiratory system drug revenue amounted to 26.09 million yuan, reflecting a growth of 18.46% compared to the previous year [1] Dividend Distribution - The company declared a cash dividend of 1.46 yuan for every 10 shares to all shareholders [1]